Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Jose Cuervo: Salida a bolsa
Jansat Mayench, Oriol; Carbonell López; Óscar; Rahnema Alavi, AhmadCaso F-975FinanzasLa salida a bolsa de Jose Cuervo (JC) en febrero de 2017 marcó todo un hito en el mundo del tequila por el hecho de ser la primera empresa tequilera del mundo en salir a bolsa. La salida de la empresa mexicana fue especialmente relevante porque se produjo meses después de la llegada a la Casa Blanca del presidente Donald Trump, que había criticado al Gobierno mexicano y había planteado la necesidad de renegociar el Tratado de Libre Comercio de Am...Desde 8,20 €
-
Jose Cuervo: Going Public
Jansat Mayench, Oriol; Carbonell López; Óscar; Rahnema Alavi, AhmadCaso F-975-EFinanzasThe initial public offering of José Cuervo (JC) in February 2017 marked a milestone in the world of tequila, as the first tequila company in the world to go public. The listing of the Mexican company was especially relevant because it took place months after the arrival of President Donald Trump to the White House. He had criticized the Mexican government and the need to renegotiate the North American Free Trade Agreement (NAFTA). The listing led...Desde 8,20 €
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCaso DARDEN-F-1715-EFinanzasThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Desde 8,20 €
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCaso DARDEN-F-1716-EFinanzasIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Desde 8,20 €